Legislature(2017 - 2018)CAPITOL 106
03/18/2017 03:00 PM House HEALTH & SOCIAL SERVICES
Note: the audio
and video
recordings are distinct records and are obtained from different sources. As such there may be key differences between the two. The audio recordings are captured by our records offices as the official record of the meeting and will have more accurate timestamps. Use the icons to switch between them.
| Audio | Topic |
|---|---|
| Start | |
| HB159 | |
| SB91 | |
| HB103 | |
| Adjourn |
* first hearing in first committee of referral
+ teleconferenced
= bill was previously heard/scheduled
+ teleconferenced
= bill was previously heard/scheduled
| *+ | HB 159 | TELECONFERENCED | |
| + | TELECONFERENCED | ||
| + | SB 91 | TELECONFERENCED | |
| += | HB 103 | TELECONFERENCED | |
HB 159-OPIOIDS;PRESCRIPTIONS;DATABASE;LICENSES
3:03:59 PM
CHAIR SPOHNHOLZ announced that the first order of business would
be HOUSE BILL NO. 159, "An Act relating to the prescription of
opioids; establishing the Voluntary Nonopioid Directive Act;
relating to the controlled substance prescription database;
relating to the practice of dentistry; relating to the practice
of medicine; relating to the practice of podiatry; relating to
the practice of osteopathy; relating to the practice of nursing;
relating to the practice of optometry; relating to the practice
of veterinary medicine; related to the duties of the Board of
Pharmacy; and providing for an effective date."
3:04:59 PM
JAY BUTLER, MD, Chief Medical Officer/ DPH Director, Central
Office, Division of Public Health, Department of Health and
Social Services, stated that there had been a fourfold increase
in the number of opioid associated deaths in the past 20 years.
He declared that this was an opioid epidemic, pointing out that
no other cause of death had increased so remarkably over such a
short period of time. He reported that there was also an
increase in the rates of Hepatitis C, as well as other burdens
on the health care system associated with increased use of
opioids, both legal and illicit. He said that there were many
things that had to be done, which would require a multi-faceted
approach. He declared that it was necessary to address the
needs of people who were currently struggling with addiction,
and to prevent addiction through more evidence based prescribing
practices, control the flood of prescription opioids in the
community, and address the access to treatment and the de-
stigmatization by improving provider knowledge. He reported
that there had been an increase in illicit opioid use, beginning
with heroin in the past five years, and more recently with
fentanyl and other synthetic opioids. He noted that 80 percent
of heroin users started opioid use with prescription
painkillers. He said that HB [159] aligned with many
prescribing guidelines delivered to the legislature from the
health care boards through Senate Bill 74 in 2016, as well as
the Centers for Disease Control and Prevention pain management
guidelines, and the Surgeon General's report on alcohol, drugs,
and health. He added that recent statements from the American
Medical Association and the American Dental Association, as well
as recommendations for evidence based improvement and
prescription drug monitoring from the PEW Charitable Trust also
supported these guidelines.
DR. BUTLER offered to outline the proposed bill for three
particular areas: patients, providers, and the prescription drug
monitoring program. He said that proposed HB [159] empowered
patients in two ways, it provided an option for those who did
not wish to be prescribed opioids to communicate that preference
to the providers by way of a voluntary revocable opioid advanced
directive which could be placed on the medical record. He
shared that this had been a request from the recovery community,
describing the challenges they faced in interactions with the
health care system when a provider was unaware that the patient
was in recovery. He shared that the second way was that it
allowed patients to request that the pharmacist dispense less
than the total prescribed amount. He said that a partial fill
was authorized under federal law, with a goal to affirm the
rights of the patient and the authority of the pharmacist. He
said that a portion of the continuing professional education
that health care providers must receive would include a section
of at least two hours designated on pain management and the
basics of addiction medicine. He explained that the renewal of
a medical license required at least 40 hours of continuing
medical education credit. He said that the second component for
providers was a setting of dispensing limits for the initial
opioid prescription to no more than 7 days. He added that the
proposed bill did allow exceptions, when in the professional
judgment of the provider, a longer supply was necessary due to
chronic pain, severe acute pain, cancer pain, or palliative
care, or when a longer supply was necessary due to travel or
other logistical barriers. The third component was for changes
to the prescription drug monitoring program, a data base
accessible to prescribers and dispensers, in order to share
information about controlled substances. He declared that the
data base was secure and confidential, and met the requirements
of the Health Insurance Portability and Accountability Act
(HIPAA). He added that this database was not openly available
to law enforcement without appropriate search warrant authority.
DR. BUTLER said that the proposed bill authorized the pharmacy
board to issue routine periodic confidential reports to
prescribers to provide feedback on their prescribing practices
relative to those of their peers. These "report cards" were a
good way to provide feedback for providers for their own
prescribing habits. He said that this had been proven effective
in other states for reducing the number of excessive
prescriptions with other substances. He stated that the second
component of the changes to the prescription drug monitoring
program (PDMP) was for clarification to include veterinarians
who prescribe opioids to register and use the monitoring
program. He referenced recent media reports regarding attempts
to get opioid medications from veterinarians. He explained that
the third component was to make the PDMP a more useful tool by
providing that pharmacists update the data on a daily, rather
than weekly, basis. He stated that the proposed bill had a
zero-fiscal note from the Department of Health and Social
Services and the Department of Corrections, and a one-time cost
of $27,500 from the Department of Commerce, Community & Economic
Development to cover legal costs to amend the regulations and
for printing. He directed attention to a letter of support from
the Alaska Dental Society.
REPRESENTATIVE TARR asked if there had been a response from
pharmacists regarding the more frequent updating of PDMP.
DR. BUTLER said that there had been this discussion with the
pharmacists and that DHSS shared concern for any increased
burden on the smaller pharmacies. He explained that there could
be a delay for this requirement to take effect. He pointed out
that some of the larger, more automated pharmacies already
updated more frequently than currently required by law.
3:16:58 PM
CHAIR SPOHNHOLZ asked about the option for patients to decline
the full prescription amount, as it seemed counter intuitive to
ask permission to accept less medicine than prescribed. She
asked if that was not currently possible.
DR. BUTLER offered his belief that "it depends on who you ask"
and that federal law had recently changed, which clarified that
pharmacists could do a partial fill at the request of the
patient.
REPRESENTATIVE KITO pointed out that there were certain
medications which required the full regimen to be effective,
which could lead to some confusion.
DR. BUTLER acknowledged and stated that the law specified for
federally designated Schedule 2 controlled substances. He said
that this use for full regimen may have inadvertently lead to
patient confusion with opioid prescriptions.
3:19:16 PM
DR. BUTLER paraphrased from the Sectional Analysis [Included in
members' packets], which read:
Sec. 1 Adds a new Chapter 55, Voluntary Nonopioid
Directive Act, to AS 13, Decedents' estates,
guardianships, transfers, trusts, and health care
decisions, that provides an option for patients to
execute a Voluntary Nonopioid Directive that would
allow a person in recovery (or for other reasons) to
make clear the person's desire not to be administered
an opioid. A person, guardian, conservator or other
appointed person may revoke a directive at any time.
The person would provide this confidential information
to a health care provider or hospital on a form
provided by the Department of Health of Social
Services. The department would promulgate regulations
on procedures, confidentiality, and exemptions for
emergency or substance misuse treatment. Providers are
not liable for following a directive. Prescriptions
are assumed to be valid; pharmacists are not liable
for dispensing a controlled substance in contradiction
to a directive. The directive does not alter an
advance health care directive, limit opioid overdose
drugs, or limit treatment for substance abuse or
opioid dependence.
Sec. 2-25 Amend AS 08, Business and Professions, for
the Boards of Dentistry, Medicine, Nursing, and
Optometry to
• Require two (2) hours of pain management and opioid
misuse and addiction instruction;
• Disciplinary actions for prescribing or dispensing
an opioid in excess of the maximum dosage allowed by
law or violated a law related to drugs, regardless of
any criminal action;
• Set the maximum dosage for initial opioid
prescriptions at a seven-day supply unless, in the
practitioner's professional judgment, it is necessary
for chronic pain management or a patient is unable to
access a practitioner in time to refill the
prescription; and
• Require, for a minor under 18 years of age, the
practitioner discuss with the parent or guardian why
the prescription is necessary and the risks associated
with opioid use.
Sec. 26-27 Amend AS 08.80 for the Board of Pharmacy to
• Register with the Prescription Drug Monitoring
Database (PDMP) with or without a federal Drug
Enforcement Administration registration number; and
• Allow pharmacists to dispense less than the
prescribed amount of a schedule II or III controlled
substance at a person's request; the pharmacists would
inform the prescribing practitioner and the
Prescription Drug Monitoring Database.
Sec. 28 Amends AS 08.98 for the Board of Veterinary
Medicine to • Register with the Prescription Drug
Monitoring Database if the veterinarian has a federal
Drug Enforcement Administration number; and
• Identify resources and educational materials for
veterinarians to identify clients at risk for opioid
misuse or diversion of prescribed opioids.
Sec. 29-36 Amend AS 17.30, Controlled Substances, to
change the frequency pharmacists report to the
Prescription Drug Monitoring Database from weekly to
daily; remove the prohibition on sharing information
with the federal government. The pharmacy board may
provide a confidential unsolicited notification in
summary form to a practitioner's licensing board which
includes the basis for the notification. The
notification must be provided to the practitioner as
well.
Sec. 37 Directs the Department of Health and Social
Services to draft regulations to implement the
Voluntary Nonopioid Directive Act.
Sec. 38 Repeals sunset dates in sections 52 and 73 of
Ch. 25, SLA 2016 (SB 74).
Sec. 39-40 Set an immediate effective date and provide
an effective date for regulations.
3:28:24 PM
REPRESENTATIVE EASTMAN asked for the type of information on the
report cards and whether the confidentiality was discoverable in
any legal action.
DR. BUTLER explained that the report cards, as used in other
states, would compare the usage over the previous 12 months with
other providers. He replied that he did not know if this was
discoverable in a legal situation.
REPRESENTATIVE EASTMAN directed attention to page 7, [lines 8 -
9] of the proposed bill, and questioned whether there should be
sanctions "regardless of whether there has been a criminal
action or patient harm." He expressed his concern, as there was
the possibility of easily breaking one of many, many laws. He
asked if this was opening up the providers to liability.
Although he was unsure of the implications, he suggested this
might require the hiring of extra staff to deal with potential
technical violations, or the increasing of insurance coverage.
He asked for the reason behind this language.
DR. BUTLER offered his understanding that this language was not
new in this bill.
REPRESENTATIVE TARR directed attention to page 28, Section 36,
of the proposed bill, and stated that she was supportive of the
idea that providers be responsible, benchmark their practice
against others, and adjust their own prescribing practices
accordingly. She pointed out that the language was permissive
and not required, and asked if this should be required. She
declared that providers were part of the solution, as they
recognized that there were alternative options for their
patients to address health care needs.
DR. BUTLER explained that the primary goal of Section 36 of the
proposed bill was to provide authority to the Board of Pharmacy
to issue the report cards, and whether or not it was a mandate
was a matter of ideology. He said that, as the issuance of
these types of report cards was not currently allowed under
Alaska law, the desire was to establish the authority to do so.
REPRESENTATIVE TARR asked if the board had a better
understanding for whether this would be voluntary. She asked if
these were the recommendations from the task force.
DR. BUTLER, in reference to the Alaska Opioid Policy Task Force,
said that a number of its recommendations were used in the bill.
3:35:28 PM
CHAIR SPOHNHOLZ said that the bill would be held over.
| Document Name | Date/Time | Subjects |
|---|---|---|
| HB0159 ver A 3.6.17.pdf |
HHSS 3/18/2017 3:00:00 PM HHSS 3/25/2017 3:00:00 PM HHSS 3/30/2017 3:00:00 PM HHSS 4/4/2017 3:00:00 PM HHSS 4/11/2017 3:00:00 PM |
HB 159 |
| HB159 Sponsor Statement 3.6.17.pdf |
HHSS 3/18/2017 3:00:00 PM HHSS 3/25/2017 3:00:00 PM HHSS 3/30/2017 3:00:00 PM HHSS 4/4/2017 3:00:00 PM HHSS 4/11/2017 3:00:00 PM |
HB 159 |
| HB 159 Sectional Analysis ver A 3.6.17.pdf |
HHSS 3/18/2017 3:00:00 PM HHSS 3/25/2017 3:00:00 PM HHSS 3/30/2017 3:00:00 PM HHSS 4/4/2017 3:00:00 PM HHSS 4/11/2017 3:00:00 PM |
HB 159 |
| HB159 Fiscal Note DHSS-PHAS 3.6.17.pdf |
HHSS 3/18/2017 3:00:00 PM HHSS 3/25/2017 3:00:00 PM HHSS 3/30/2017 3:00:00 PM HHSS 4/4/2017 3:00:00 PM HHSS 4/11/2017 3:00:00 PM |
HB 159 |
| SB 91 ver A.pdf |
HHSS 3/18/2017 3:00:00 PM |
SB 91 |
| SB091 Sponsor Statement 3.16.17.pdf |
HHSS 3/18/2017 3:00:00 PM |
SB 91 |
| SB091 ver J 3.16.17.pdf |
HHSS 3/18/2017 3:00:00 PM |
SB 91 |
| SB091 Sectional Analysis ver J 3.16.17.pdf |
HHSS 3/18/2017 3:00:00 PM |
SB 91 |
| SB091 Additional Documents-Explanation of Changes, ver J 3.17.17.pdf |
HHSS 3/18/2017 3:00:00 PM |
SB 91 |
| SB091 Fiscal Note DHSS-PHAS ver J 3.16.17.pdf |
HHSS 3/18/2017 3:00:00 PM |
SB 91 |
| SB 36 Opposition Letter Coulter MD vs. SB36 HB103.pdf |
HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM SFIN 3/14/2017 9:00:00 AM |
HB 103 SB 36 |
| HB 103 Draft Proposed Blank CS ver D 3.13.2017.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Explanation of Changes (CS) 2.22.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Letters of Support 2.22.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Fiscal Note DCCED--DCBPL 3.13.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Sectional Analysis (CS) 2.22.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Sponsor Statement 2.22.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Supporting Document Ohio State Optometry Curriculum 2.22.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Supporting Document Medical Liability Premiums Fact Sheet 2.22.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Supporting Document Regulation Flow Chart 3-10-17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Supporting Document-Board of the Examiners in Optometry.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Supporting Document-Optometrists Practicing in AK 2.22.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Supporting Documents Optometry Education Flyer 2.22.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB103 Career Guide Optometry 2.22.17.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB103 Letters of Opposition-Support.pdf |
HHSS 3/14/2017 3:00:00 PM HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |
| HB 103 Opposing Document--Letters 3.15.17.pdf |
HHSS 3/16/2017 3:00:00 PM HHSS 3/18/2017 3:00:00 PM |
HB 103 |